Corvus Pharmaceuticals, Inc. (CRVS) Upgraded to Hold at Zacks Investment Research
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Tuesday.
According to Zacks, “Corvus Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of immuno-oncology therapies to harness the immune system to attack cancer cells. Its products include CPI-444, Adenosine production inhibitor, Adenosine A2B antagonist and Interleukin-2 (IL-2)-inducible T cell kinase (ITK) inhibitors. Corvus Pharmaceuticals, Inc. is based in Burlingame, California. “
CRVS has been the subject of a number of other research reports. Cowen and Company reaffirmed an “outperform” rating on shares of Corvus Pharmaceuticals in a report on Tuesday, July 4th. Credit Suisse Group lowered their target price on shares of Corvus Pharmaceuticals from $26.00 to $17.00 and set an “outperform” rating for the company in a report on Tuesday, July 4th. Finally, Wedbush reaffirmed an “outperform” rating and set a $26.00 target price on shares of Corvus Pharmaceuticals in a report on Tuesday, August 8th. Two analysts have rated the stock with a hold rating and three have given a buy rating to the company. Corvus Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $20.75.
Shares of Corvus Pharmaceuticals (CRVS) traded down 1.42% during midday trading on Tuesday, hitting $16.66. The stock had a trading volume of 89,574 shares. Corvus Pharmaceuticals has a 52 week low of $13.01 and a 52 week high of $17.64. The stock’s market cap is $348.76 million. The stock has a 50-day moving average of $16.57 and a 200 day moving average of $16.57.
Corvus Pharmaceuticals (NASDAQ:CRVS) last released its earnings results on Thursday, August 3rd. The company reported ($0.73) EPS for the quarter, topping analysts’ consensus estimates of ($0.76) by $0.03. Analysts anticipate that Corvus Pharmaceuticals will post ($3.18) EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This story was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another publication, it was copied illegally and reposted in violation of United States and international copyright and trademark legislation. The legal version of this story can be accessed at https://www.americanbankingnews.com/2017/10/10/corvus-pharmaceuticals-inc-crvs-upgraded-to-hold-at-zacks-investment-research.html.
Hedge funds have recently made changes to their positions in the company. TIAA CREF Investment Management LLC grew its holdings in shares of Corvus Pharmaceuticals by 43.3% in the 1st quarter. TIAA CREF Investment Management LLC now owns 7,181 shares of the company’s stock valued at $149,000 after buying an additional 2,170 shares during the period. Russell Investments Group Ltd. grew its holdings in shares of Corvus Pharmaceuticals by 29.3% in the 2nd quarter. Russell Investments Group Ltd. now owns 9,286 shares of the company’s stock valued at $112,000 after buying an additional 2,105 shares during the period. New York State Common Retirement Fund grew its holdings in shares of Corvus Pharmaceuticals by 2,269.1% in the 2nd quarter. New York State Common Retirement Fund now owns 9,500 shares of the company’s stock valued at $115,000 after buying an additional 9,099 shares during the period. Endurant Capital Management LP acquired a new position in shares of Corvus Pharmaceuticals in the 1st quarter valued at $282,000. Finally, Oxford Asset Management acquired a new position in shares of Corvus Pharmaceuticals in the 1st quarter valued at $287,000. 83.63% of the stock is owned by institutional investors.
Corvus Pharmaceuticals Company Profile
Corvus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology therapies. The Company is developing drugs and antibodies that block crucial immune checkpoints and reprogram immune T-cells. The Company has a pipeline of four immuno-oncology programs, three of which focus on the adenosine-cancer axis to modulate an immune response.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Corvus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.